Zacks Research Issues Optimistic Forecast for BHC Earnings

Bausch Health Companies Inc. (NYSE:BHC) – Research analysts at Zacks Research increased their Q3 2026 earnings per share (EPS) estimates for Bausch Health Companies in a research report issued on Tuesday, October 22nd. Zacks Research analyst R. Department now expects that the company will post earnings per share of $1.30 for the quarter, up from their prior forecast of $1.29. The consensus estimate for Bausch Health Companies’ current full-year earnings is $3.61 per share. Zacks Research also issued estimates for Bausch Health Companies’ FY2026 earnings at $4.95 EPS.

Several other equities analysts have also commented on the company. Jefferies Financial Group cut their price target on Bausch Health Companies from $13.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday, August 7th. Piper Sandler lowered Bausch Health Companies from a “neutral” rating to an “underweight” rating and cut their price target for the company from $9.00 to $3.00 in a research note on Friday, August 2nd. Evercore ISI raised Bausch Health Companies to a “hold” rating in a research report on Tuesday, October 15th. StockNews.com raised Bausch Health Companies from a “hold” rating to a “buy” rating in a research report on Friday. Finally, Royal Bank of Canada dropped their price objective on Bausch Health Companies from $10.00 to $8.50 and set a “sector perform” rating on the stock in a research report on Friday, August 2nd. One analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, Bausch Health Companies presently has a consensus rating of “Hold” and a consensus price target of $7.33.

Bausch Health Companies Trading Up 0.6 %

Shares of Bausch Health Companies stock opened at $8.12 on Wednesday. The firm has a market cap of $2.93 billion, a P/E ratio of -6.55 and a beta of 0.77. Bausch Health Companies has a 12 month low of $3.96 and a 12 month high of $11.46. The stock’s fifty day moving average price is $7.22 and its 200-day moving average price is $7.09.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings results on Thursday, August 1st. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.89 by $0.09. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.33 billion. Bausch Health Companies had a negative return on equity of 742.06% and a negative net margin of 5.12%. During the same quarter last year, the firm posted $0.81 earnings per share.

Institutional Investors Weigh In On Bausch Health Companies

Institutional investors have recently added to or reduced their stakes in the business. International Assets Investment Management LLC acquired a new stake in shares of Bausch Health Companies during the third quarter worth about $1,910,000. Creative Planning lifted its holdings in shares of Bausch Health Companies by 16.9% during the third quarter. Creative Planning now owns 55,351 shares of the company’s stock worth $452,000 after purchasing an additional 7,995 shares during the period. Clearline Capital LP acquired a new stake in shares of Bausch Health Companies during the second quarter worth about $6,881,000. Mackenzie Financial Corp lifted its holdings in shares of Bausch Health Companies by 111.0% during the second quarter. Mackenzie Financial Corp now owns 2,381,888 shares of the company’s stock worth $16,612,000 after purchasing an additional 1,252,834 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Bausch Health Companies by 2.0% during the second quarter. The Manufacturers Life Insurance Company now owns 246,808 shares of the company’s stock worth $1,719,000 after purchasing an additional 4,944 shares during the period. Institutional investors and hedge funds own 78.65% of the company’s stock.

Insiders Place Their Bets

In other Bausch Health Companies news, EVP Seana Carson sold 13,370 shares of the firm’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $6.21, for a total value of $83,027.70. Following the completion of the sale, the executive vice president now owns 435,198 shares of the company’s stock, valued at approximately $2,702,579.58. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 8.12% of the company’s stock.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.